Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Public ClinicalTrials.gov record NCT01784562. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Study identification
- NCT ID
- NCT01784562
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Bayer
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Adempas (Riociguat, BAY63-2521) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 5, 2016
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Los Angeles | California | 90073 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Weston | Florida | 33331 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Iowa City | Iowa | 52242-1089 | — |
| Not listed | Baltimore | Maryland | 21201-1595 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Boston | Massachusetts | 02118 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Omaha | Nebraska | 68131 | — |
| Not listed | Newark | New Jersey | 07112 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Columbus | Ohio | 43221 | — |
| Not listed | Fairfield | Ohio | 45014 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| Not listed | Providence | Rhode Island | 02903-4900 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | El Paso | Texas | 79902 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01784562, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01784562 live on ClinicalTrials.gov.